The role of the Biostatistics Core is to support the investigators of the SPORE in Prostate Cancer in their research efforts, including laboratory experiments and the design and analysis of clinical trials. In preclinical studies, core members will assist in the formulation of the experimental design and in the analysis and interpretation of the data at the conclusion of the study. In the clinical trial design phase, a core member will conduct a protocol review with the principal investigator. Based on this review, a statistical section for the protocol will be provided, outlining major scientific objectives, population to be studied, primary and secondary endpoints, experimental design, a randomization procedure if necessary, analysis plans, and a targeted sample size justified in probabilistic terms. At the conclusion of the trial, data analyses will be performed to assess outcomes of the primary and secondary endpoints stated in the protocol.
The specific aims of the Biostatistics Core are to:
Aim 1 : Contribute to the design and analysis of laboratory-based prostate cancer research Aim 2: Contribute to the design and analysis of clinical studies in prostate cancer Aim 3: Develop statistical methodology that will assist in the advancement of prostate cancer research
The Biostatistics Core assists the research efforts of the MSKCC SPORE in Prostate Cancer investigators, contributing to the design and analysis of clinical and laboratory research and the development of valid conclusions. The core provides statistical analysis and consultancy as well as ongoing quality assurance. The core has also established a data quality working group to improve the quality of SPORE data.
|Cheal, Sarah M; Punzalan, Blesida; Doran, Michael G et al. (2014) Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcino Eur J Nucl Med Mol Imaging 41:985-94|
|Bancroft, Elizabeth K; Page, Elizabeth C; Castro, Elena et al. (2014) Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol 66:489-99|
|Sjoberg, Daniel D (2014) Toward a Smarter Prostate Cancer Screening Program. Eur Urol :|
|Ehdaie, Behfar; Vertosick, Emily; Spaliviero, Massimiliano et al. (2014) The impact of repeat biopsies on infectious complications in men with prostate cancer on active surveillance. J Urol 191:660-4|
|Ahmad-Tajudin, Asilah; Adler, Belinda; Ekstrom, Simon et al. (2014) MALDI-target integrated platform for affinity-captured protein digestion. Anal Chim Acta 807:1-8|
|Vickers, Andrew J (2014) Clinical trials in crisis: Four simple methodologic fixes. Clin Trials 11:615-21|
|Bryant, Richard J; Lilja, Hans (2014) Emerging PSA-based tests to improve screening. Urol Clin North Am 41:267-76|
|Vertosick, Emily A; Poon, Bing Ying; Vickers, Andrew J (2014) Relative value of race, family history and prostate specific antigen as indications for early initiation of prostate cancer screening. J Urol 192:724-8|
|Vickers, Andrew J; Pepe, Margaret (2014) Does the net reclassification improvement help us evaluate models and markers? Ann Intern Med 160:136-7|
|Shi, Yuji; Wang, Junru; Chandarlapaty, Sarat et al. (2014) PTEN is a protein tyrosine phosphatase for IRS1. Nat Struct Mol Biol 21:522-7|
Showing the most recent 10 out of 310 publications